IACTA APAC

Bringing innovation to China, Japan, Korea, and the Asia-Pacific region

IACTA APAC is an innovative new company exclusively focused on bringing cutting edge differentiated technology to the entire Asia-Pacific region

See how

IACTA APAC is a dramatic pharmaceutical accelerator for early stage companies

For clinic-ready ophthalmology programs, we can perform clinical studies faster, cheaper, and with a go-to-market partner for the Asia-Pacific region.

Ophthalmology regulatory reform

We believe recent changes in China’s regulatory structure, specifically its expedited pathway for investigational new drugs and its openness to participating in global clinical trials, allows for a new, faster, and more cost efficient model for drug development.

IACTA APAC is focused on bringing 1st world cutting edge medicines to Asia on a parallel track with that of the United States. We believe this will dramatically accelerate innovation for Ophthalmology worldwide and even ultimately accelerate the timing of drug approvals in the United States.

With access to the IACTA compounds, we are now well-positioned to accelerate the development of IC 265 and IC 270 for approval in China and other markets in Southeast Asia. The efficacy of IC 265 and IC 270 is supported by significant clinical data and it is a natural fit for our robust product development strategy

DR. BENJAMIN LI

CHAIRMAN OF ZKO

Become one of our

global partners

We are actively looking for global corporate partners who want to accelerate their drug development programs.

Let’s connect

DAMON BURROWS

FOUNDER / CHIEF EXECUTIVE OFFICER